Talzenna
Chemical Name | talazoparib |
Dosage Form | Capsule (oral; 0.25 mg, 0.5 mg, 1 mg) |
Drug Class | Inhibitors |
System | Female reproductive |
Company | Pfizer Inc. |
Approval Year | 2018 |
Indication
- To treat deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.